纳武利尤单抗治疗持续性或复发性宫颈癌的II期评估
这项II期试验评估纳武利尤单抗在铂类化疗后持续性/复发性宫颈癌中的疗效与耐受性,26例入组、25例可评估,客观缓解率仅4%,中位缓解持续时间3.8个月,安全性可接受。
要点
- 单药纳武利尤单抗在经铂类治疗的持续性/复发性宫颈癌中抗肿瘤活性低。
- 确认部分缓解1例(4%;90%CI 0.4%-22.9%),缓解持续时间3.8个月。
- 治疗相关不良事件多见但多为1-2级,3级TRAE 6例(24%)。
核心结论
- 单药纳武利尤单抗在既往接受铂类化疗的持续性/复发性宫颈癌患者中抗肿瘤活性低,安全性可接受。
研究设计与样本
- 妇科肿瘤组开展的II期试验,采用两阶段分组序贯设计。
- 入组26例持续性/复发性宫颈癌患者,25例可评估疗效/毒性,中位年龄45岁。
- 纳武利尤单抗3 mg/kg静脉给药,每2周一次,直至疾病进展或不可耐受毒性。
主要发现
- 确认部分缓解1例(4%;90%CI 0.4%-22.9%),缓解持续时间3.8个月。
- 疾病稳定9/25例(36%;90%CI 20.2%-54.4%),中位稳定持续时间5.7个月(范围3.5-12.7)。
- 6个月估计无进展生存率和总生存率分别为16%和78.4%。
- 21例(84%)发生治疗相关不良事件,多为1-2级;6例(24%)发生3级TRAE,1例因肝毒性停药。
- 无5级TRAE,2例发生4级TRAE。
关键数值与推荐
- 关键入选标准包括持续性/复发性宫颈癌、既往系统治疗失败、ECOG PS 0-1。
- PD-L1表达(CPS≥1%)在77.3%的肿瘤样本中检出。
- 主要终点为RECIST 1.1评估的客观缓解。
临床怎么用
- 单药纳武利尤单抗不作为持续性/复发性宫颈癌的优先选择,因客观缓解率低。
- 治疗相关不良事件以1-2级为主,但需监测3级及以上毒性,尤其肝毒性。
局限性
- 样本量小(26例入组,25例可评估),结论外推受限。
- 单臂设计,无对照,无法比较与其他治疗的疗效差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Patients with persistent/recurrent cervical cancer following platinum-based chemotherapy have limited therapeutic options. The Gynecologic-Oncology-Group conducted a phase II trial to assess efficacy and tolerability of nivolumab, an immune checkpoint inhibitor, in persistent/recurrent cervical carcinoma. PATIENTS AND METHODS: Key eligibility criteria included persistent/recurrent cervical cancer, failure of prior systemic therapy and ECOG PS 0-1. Nivolumab 3 mg/kg was given IV every 2 wk. until disease progression or intolerable toxicity. Response was assessed every 8 wk. for 6 months and every 12 wk. thereafter. The primary endpoints were objective response as assessed by RECIST 1.1. The study used a 2-stage group sequential design. PD-L1 expression was evaluated in tumor specimens by immunohistochemistry (IHC) using a combined-positive-score (CPS) cutoff of ≥1%. RESULTS: Of 26 enrolled patients with persistent/recurrent cervical cancer, 25 were evaluable for response/toxicity with a median age of 45. 36% had ECOG PS of 1, and 100% had received one prior systemic chemotherapy regimen. PD-L1 expression (≥1%) was identified in 77.3% of tumor samples. As of 03/05/19, all patients were off study treatment; median follow-up for survival status was 32 months (range, 2-41.5). There were 21 (84%) patients with a treatment-related adverse event (TRAE) and most were grades 1-2. Six (24%) patients had grade 3 TRAEs with 1 discontinuing nivolumab due to hepatic toxicity. No grade 5 TRAEs occurred, and 2 patients had grade 4 TRAEs. One confirmed partial response (4%; 90% CI, 0.4%-22.9%), duration of response 3.8 months. Thirty-six percent of patients had stable disease (SD) (9/25; 90% CI, 20.2%-54.4%); the median duration of SD was 5.7 months (range, 3.5-12.7). Estimated PFS and OS at 6 months were 16% and 78.4%, respectively. CONCLUSION: Single agent nivolumab exhibited low antitumor activity and an acceptable safety profile in patients with persistent/recurrent cervical cancer previously treated with platinum-based chemotherapy.
引用
- Santin AD, Deng W, Frumovitz M, et al. Phase II evaluation of nivolumab in the treatment of persistent or recurrent cervical cancer (NCT02257528/NRG-GY002). Gynecol Oncol. 2020. PMID: 31924334. doi:10.1016/j.ygyno.2019.12.034
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。